Heart imaging study for transthyretin amyloidosis
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a new type of heart imaging scan called [68Ga]Ga-FAPI-46 PET to help doctors see and track transthyretin cardiac amyloidosis (a disease where abnormal proteins damage the heart). The scan may help identify which patients are getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) based on recent medical guidelines
- You are at least 18 years old
- You live in France and have French social security coverage
- You have not had a heart attack or myocarditis (heart inflammation) in your history
- You do not have severe aortic stenosis (a valve problem in the heart)
- You have not participated in other trials testing TTR gene-silencing therapy or amyloid-depleting treatments for ATTR-CM
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
Hear when a new Transthyretin Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.